Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer
Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This is a Phase II prospective sing-arm trial that is recruiting 60 participants from patients that have biochemical failure after radical prostatectomy with local or regional recurrence proven by PSMA PET. Participants of this study will receive molecular imaging informed radiation dose escalation to site of recurrent disease and de-escalation to uninvolved areas. Participants will be follow-up as per standard of care up to 5 years post-treatment.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: f
View:
• Men older than 18 years old.
• Histologically proven initial diagnosis of adenocarcinoma prostate cancer.
• Previous radical prostatectomy.
• Biochemical relapse with local or regional recurrence proven on PSMA PET.
• Five or less positive nodes on the PSMA PET.
• ECOG 0-1
Locations
Other Locations
Canada
Princess Margaret Cancer Center
RECRUITING
Toronto
Contact Information
Primary
Andrew McPartlin, MD
andrew.mcpartlin@uhn.ca
416-946-4501
Time Frame
Start Date: 2022-08-05
Estimated Completion Date: 2030-08
Participants
Target number of participants: 80
Treatments
Experimental: Molecular Imaging Informed Radiation Dose Escalation and De-escalation
Molecular imaging informed radiation dose escalation to sites of recurrent disease and de-escalation to uninvolved areas.
Related Therapeutic Areas
Sponsors
Leads: University Health Network, Toronto